| Ytd | 0.43% | |
| 1y | 2.87% |
| Open | 141.33 | Prev Close | 141.25 | Low | 140.02 | High | 143.55 | Mkt Cap | 14.48B |
| Vol | 1.02M | Avg Vol | 1.30M | EPS | 6.82 | P/E | 20.89 | Forward P/E | 11.99 |
| Beta | 0.40 | Short Ratio | 4.85 | Inst. Own | 102.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 12-29 | Earning | 10-28 | 50-d Avg | 152.83 | 200-d Avg | 147.26 | 1yr Est | 207.29 |
NBIX News
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing pro
Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating an
Pre-Market Stock Futures: Futures are trading higher after we started off the first full trading wee
UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers th
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-W
RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Outperf
Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and
NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovere
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences.
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-W
Reports of serious adverse events and deaths linked to Neurocrine's VYKAT XR for Prader-Willi sy
INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrat
Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and
Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a B
Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Bu
Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and
Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperfo
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-W
TD Cowen analyst Phil Nadeau maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises
Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overwe
Cantor Fitzgerald analyst Josh Schimmer maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Ove
Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and rai
Stifel analyst Paul Matteis maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises
Needham analyst Ami Fadia maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises th
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $2.85 per share which beat the a
Guggenheim analyst Brad Canino maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and rais
Wells Fargo analyst Mohit Bansal maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight
Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Bu
BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market P
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperfo
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical st
Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated impr
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHta
Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets
Nearly all individuals with intellectual and developmental disabilities experienced improvement in t
Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and
Goldman Sachs analyst Corinne Johnson reinstates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperfo
Bernstein analyst Jeffrey Walch initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) with a
Clinician survey showed 90% of patients with mild tardive dyskinesia experienced emotional, social o
JP Morgan analyst Anupam Rama maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight an
Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Bu
Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-W
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperfo
Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overwe
Guggenheim analyst Yatin Suneja reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and ma